A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR-214 in adult patients with locally advanced or metastatic solid tumors.
Unspecified Adult Solid Tumor, Protocol Specific
DRUG: NKTR-214
Safety of NKTR-214 as Evaluated by Incidence of Drug-related Adverse Events (AEs), This outcome quantifies the number and types of adverse events associated with NKTR-214., 30 days after last dose, approximately 533 days|Tolerability of NKTR-214 as Evaluated by Incidence of Dose Limiting Toxicities (DLTs), The data below reflects the incidence of Dose Limiting Toxicity Events observed in this trial., 30 days after last dose, up to 533 days
This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR-214 in adult patients with locally advanced or metastatic solid tumors.